2024
Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E. Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations. Genes 2024, 15: 934. PMID: 39062713, PMCID: PMC11276289, DOI: 10.3390/genes15070934.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseLung cancerLung diseaseDriver mutationsImproved survivalTreatment optionsChronic inflammationPathogenetic pathwaysNon-small cell lung cancerConcurrent interstitial lung diseaseCell lung cancerSites of chronic inflammationAnti-fibrotic medicationsCurrent treatment optionsIdiopathic pulmonary fibrosisDiseases associated with chronic inflammationIncidence of lung cancerPersonalized medicine approachPrompt diagnosisClinical entityNon-smallPulmonary fibrosisNSCLCSurvival ratePatientsMycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis
Lombardi F, Stewart I, Fabbri L, Adams W, Kawano-Dourado L, Ryerson C, Jenkins G, Consortium R, Cavalcanti A, Mojibian A, Bravery A, Goodwin A, Etges A, Boshoff A, Guenther A, Briggs A, Palmer A, Wilson A, Crawshaw A, Anna-MariaHoffmann-Vold A, Holland A, Gordon A, Prasse A, Tzouvelekis A, Trachalaki A, Wells A, Nair A, Wendelberger B, Hope-Gill B, Gooptu B, Baldi B, Crestani B, Polanczyk C, Vancheri C, Robalo C, Summers C, Grainge C, Ryerson C, von Garnier C, Huntley C, Ravaglia C, Valenzuela C, Hayton C, McCarthy C, Chambers D, Wang D, Bablis D, Thicket D, Turner D, Talwar D, Adegunsoye D, Anand D, Dhasmana D, Parek D, Griffiths D, Richards D, Santucci E, Bendstrup E, Balestro E, Tsitoura E, Falaschetti E, Karlsen E, Gupta E, Farrand E, Khan F, Chua F, Martinez F, Bonella F, Lombardi F, Hunninghake G, Saini G, Chalmers G, Jenkins G, Gudmundsson G, Collard H, Parfrey H, Prosch H, Fainberg H, Adamali H, Stewart I, Forrest I, Glaspole I, Bauer-Ventura I, Noth I, Cox I, Strambu I, Sellares J, Eaden J, Johnston J, Swigris J, Blaikley J, Kim J, Chung J, Lasky J, Jacob J, Lee J, Behr J, Storrer K, Negrelli K, Lewandowska K, Johnson K, Antoniou K, Hostettler K, Johannson K, Hurley K, Hett K, Schwarzkopf L, Fabbri L, Price L, Pearmain L, Kawano-Dourado L, Galvin L, Spencer L, Watson L, Crowley L, Richeldi L, Piccari L, Chambour M, Molina-Molina M, Jones M, Spears M, Toshner M, Wijsenbeek-Lourens M, Brutsche M, Vasakova M, Quintana M, Gibbons M, Henry M, Keane M, Kreuter M, Hatieganu M, Sadatsafavi M, Kaminski N, Chaudhuri N, Weatherley N, Hirani N, Babes O, Spagnolo P, Beirne P, Bryce P, George P, Molyneaux P, Ortega P, Crisan-Dabija R, Maida R, Borie R, Lewis R, Rolo R, Guler S, Paganoni S, Singh S, Freitas S, Piciucchi S, Malik S, Barratt S, Hart S, Dal Corso S, Fletcher S, Stanel S, Bianchi S, Jones S, Adams W. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis. BMJ Open Respiratory Research 2024, 11: e002163. PMID: 38413120, PMCID: PMC10973691, DOI: 10.1136/bmjresp-2023-002163.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseMycophenolate mofetilRandomised controlled trialsPrimary endpointLung diseasePulmonary functionEfficacy of mycophenolate mofetilPreservation of pulmonary functionInterstitial lung disease diagnosisMMF efficacyPrimary endpoint analysisProspective observational studySystematic reviewNo language restrictionsGrading of RecommendationsAzathioprine efficacyConcomitant steroidsAzathioprine treatmentImmunomodulatory treatmentRandomised controlled trial designSecondary endpointsPlacebo comparatorRetrospective studyAzathioprineSubgroup analysis
2023
Increased Levels of Galectin-3 in Critical COVID-19
Nikitopoulou I, Vassiliou A, Athanasiou N, Jahaj E, Akinosoglou K, Dimopoulou I, Orfanos S, Dimakopoulou V, Schinas G, Tzouvelekis A, Aidinis V, Kotanidou A. Increased Levels of Galectin-3 in Critical COVID-19. International Journal Of Molecular Sciences 2023, 24: 15833. PMID: 37958814, PMCID: PMC10650562, DOI: 10.3390/ijms242115833.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCritical COVID-19ICU mortalityGalectin-3Patient cohortPrognostic accuracyCOVID-19Galectin-3 serum levelsIntensive care unit admissionHospitalized COVID-19 patientsCritical COVID-19 patientsGalectin-3 measurementCare unit admissionGalectin-3 levelsIndependent risk factorMultiple organ injurySevere COVID-19Second patient cohortGreek university hospitalGalectin-3 concentrationsUnit admissionActive diseaseRespiratory failureHospital admissionOrgan injury